CoChat

Small Molecule Inhibitor of CBFβ-RUNX Binding for RUNX Transcription Factor Driven Cancers

Open access
Illendula, Anuradha, Gilmour, Jane, Grembecka, Jolanta, Tirumala, Venkata Sesha Srimath, Boulton, Adam, Kuntimaddi, Aravinda, Schmidt, Charles, Wang, Lixin, Pulikkan, John A., Zong, Hongliang, Parlak, Mahmut, Kuscu, Cem, Pickin, Anna, Zhou, Yunpeng, Gao, Yan, Mishra, Lauren, Adli, Mazhar, Castilla, Lucio H., Rajewski, Roger A., Janes, Kevin A., Guzman, Monica L., Bonifer, Constanze, Bushweller, John H. · 2016 · EBioMedicine
Cited by 99

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Transcription factors have traditionally been viewed with skepticism as viable drug targets, but they offer the potential for completely novel mechanisms of action that could more effectively address the stem cell like properties, such as self-renewal and chemo-resistance, that lead to the failure of traditional chemotherapy approaches. Core binding factor is a heterodimeric transcription factor comprised of one of 3 RUNX proteins (RUNX1-3) and a CBFβ binding partner. CBFβ enhances DNA binding of RUNX subunits by relieving auto-inhibition. Both RUNX1 and CBFβ are frequently mutated in human leukemia. More recently, RUNX proteins have been shown to be key players in epithelial cancers, suggesting the targeting of this pathway could have broad utility. In order to test this, we developed small molecules which bind to CBFβ and inhibit its binding to RUNX. Treatment with these inhibitors reduces binding of RUNX1 to target genes, alters the expression of RUNX1 target genes, and impacts cell survival and differentiation. These inhibitors show efficacy against leukemia cells as well as basal-like (triple-negative) breast cancer cells. These inhibitors provide effective tools to probe the utility of targeting RUNX transcription factor function in other cancers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ebiom.2016.04.032

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 99

Metadata

Authors
Illendula, A., Gilmour, J., Grembecka, J., Tirumala, V. S. S., Boulton, A., Kuntimaddi, A., Schmidt, C., Wang, L., Pulikkan, J. A., Zong, H., Parlak, M., Kuscu, C., Pickin, A., Zhou, Y., Gao, Y., Mishra, L., Adli, M., Castilla, L. H., Rajewski, R. A., Janes, K. A., Guzman, M. L., Bonifer, C., & Bushweller, J. H.
Venue
EBioMedicine
Publisher
Elsevier BV
Published
2016-06
Volume
8
Pages
117-131
ISSN
2352-3964 (ISSN-L)
OpenAlex
W2343873789
Cited by
99
References
4
FWCI
7.90
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Small Molecule Inhibitor of CBFβ-RUNX Binding for RUNX Transcription Factor Driven Cancers. https://app.cochat.ai/papers/10.1016/j.ebiom.2016.04.032
The paper
Illendula, A., Gilmour, J., Grembecka, J., Tirumala, V. S. S., Boulton, A., Kuntimaddi, A., Schmidt, C., Wang, L., Pulikkan, J. A., Zong, H., Parlak, M., Kuscu, C., Pickin, A., Zhou, Y., Gao, Y., Mishra, L., Adli, M., Castilla, L. H., Rajewski, R. A., . . . Bushweller, J. H. (2016). Small Molecule Inhibitor of CBFβ-RUNX Binding for RUNX Transcription Factor Driven Cancers. EBioMedicine. https://doi.org/10.1016/j.ebiom.2016.04.032

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.